Mimedx (MDXG) Stock
Publicly traded company. Here's the price, business snapshot, and what's worth knowing about Mimedx in October 2026.
MiMedx Group, Inc. is a placental biologics company focused on providing a portfolio of products for applications in the wound care, burn, and surgical sectors of healthcare. Its product portfolio categories include Wound Care and Surgical. The Wound Care products include EPIFIX and EPIEFFECT, which are marketed for external use, such as in advanced wound care applications. Its EPICORD, EPICORD Expandable and EPIEFFECT product lines also offer an alternative treatment option to address larger, deeper wounds. Its Surgical and Other product offering includes AMNIOFIX and AMNIOEFFECT, which are used in a variety of applications and surgical settings, including lower extremity repair, plastic surgery, vascular surgery and multiple orthopedic repairs and reconstructions. It also offers HELIOGEN, an advanced bovine collagen matrix containing type I and type III collagen that is intended for the management of moderately to heavily exudating wounds and to control minor bleeding.
Mimedx (MDXG) Stock Forecast
Analyst price target, next 12 months
$10.50
+171.3% vs today's $3.87
Price range over the last 12 months
Close to its 12-month low
Analysts covering Mimedx have a consensus 12-month target of $10.50, above the current price of $3.87.
Analyst targets are opinions, not guarantees. Capital at risk. Data as of 27 Oct 2026.
Source: Analyst sentiment is provided by Refinitiv Ltd, a global leader in financial market data with over 40k business clients. Refinitiv Ltd is an independent third party to Nemo. This is not advice.
Sixth Month Growth Performance
Stock Performance Snapshot
Analyst Rating
Analysts recommend buying MIMEDX Group's stock with a target price of $10.5, indicating strong potential for growth.
Financial Health
MIMEDX is producing good revenue and cash flow, with a strong profit margin indicating solid performance.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Baskets Featuring MDXG
Drug Pricing Deals Drive US Manufacturing in 2025
Johnson & Johnson secured a deal with the U.S. government to lower drug prices in exchange for tariff exemptions, expanding on a major policy trend. This theme identifies opportunities among pharmaceutical companies and domestic manufacturers benefiting from government incentives to onshore production.
Published: 9 January 2026
Explore BasketWhy invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
